Signifier Medical Technologies Launches New Version of Its Sleep Therapy

LONDON—Signifier Medical Technologies Limited, which makes medical technology for sleep-disordered breathing, today announced the introduction of its newest SKU, 18010, which features a hardware remote control specifically designed to meet Centers for Medicare & Medicaid Services (CMS) requirements for reimbursement. The company said this development means eXciteOSA therapy can be more readily accessed by Medicare and Medicaid patients.

“EXciteOSA is a life-changing device helping patients address a root cause of sleep apnea and other sleep disorders. This milestone underscores our ongoing commitment to innovation, as well as our determination to expand treatment access through alignment with CMS requirements,” said Mujtaba Chohan, head of finance and director at Signifier. “(This) announcement is a testament to the collaborative efforts of our multidisciplinary teams, and I am proud of the progress we’ve made in ensuring that these therapies are available and affordable to as many people as possible.”

In a news release, the company highlighted the following features: 

• Medicare and Medicaid Reimbursement: By introducing this hardware remote control, Signifier has met the criteria to classify its eXciteOSA therapy under CMS HCPCS Codes (E0490 and E0491).
• Hardware Innovation: The remote control simplifies device usage for patients, offering a user-friendly interface that aligns with the durable medical equipment (DME) requirements set forth by Medicare and Medicaid.
• Consistent, Effective Treatment Experience: The new remote control maintains the same clinically proven efficacy and convenience that patients expect from eXciteOSA, making therapy more accessible without altering its effectiveness.
   

Signifier says the move builds on recent momentum, including eXciteOSA gaining Medicaid coverage to serve patients in Georgia and South Carolina. EXciteOSA claims to be the first FDA-authorized daytime therapy that treats a root cause of snoring and mild obstructive sleep apnea. Using non-invasive neuromuscular electrical stimulation, it strengthens the tongue muscles to prevent airway collapse during sleep.